Statement to the Media: Lilly ICOS Pleased with European Patent Office's Decision to Affirm Revocation of Pfizer's Patent on Treatment of Erectile Dysfunction.
PR Newswire Europe, February, 2005
BOTHELL, Washington and INDIANAPOLIS, Indiana, February 10 /PRNewswire/ -- Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of Cialis(R) (tadalafil), a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), is pleased with the European Patent Office's (EPO) final decision to affirm its earlier decision to revoke Pfizer's method-of-use patent - European Patent EP-B-0702555, containing claims for the use of any PDE inhibitor for the manufacture of an oral treatment for ED. The ruling was made following a three-day hearing by a Board of Appeal of the EPO, which concluded on Thursday, February 3, 2005. Lilly ICOS offered the following statement regarding the decision:
- This decision by the Board of Appeal confirmed our view that the...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
